# The effectiveness of long-term physical activity after exercise and educational programs on breast cancer-related **176P** lymphoedema: secondary analyses from a randomized controlled trial: The Setouchi Breast Project 10. Shogo Nakamoto<sup>1</sup>, Naruto Taira<sup>2,3</sup>, Kengo Kawada<sup>4</sup>, Daisuke Takabatake<sup>5</sup>, Yuichiro Kubo<sup>7</sup>, Yoko Suzuki<sup>1</sup>, Mari Yamamoto<sup>7</sup>, Yutaka Ogasawara<sup>4</sup>, Seiji Yoshitomi<sup>8</sup>, Kyoko Hara<sup>8</sup>, Tadahiko Shien<sup>2</sup>, Takayuki Iwamoto<sup>2</sup>, Shozo Ohsumi<sup>6</sup>, Masahiko Ikeda<sup>7</sup>, Yuri Mizota<sup>9</sup>, Seiichiro Yamamoto<sup>9</sup>, Hiroyoshi Doihara<sup>2</sup>

1. Department of General Thoracic Surgery, and Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan. 3. Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan. 6. Department of Breast Oncology, NHO Shikoku Science Center, Kochi, Japan. 6. Department of Breast Oncology, NHO Shikoku Science Center, Kochi, Japan. 6. Department of Breast Oncology, NHO Shikoku Science Center, Kochi, Japan. 6. Department of Breast Oncology, NHO Shikoku Science Center, Kochi, Japan. 6. Department of Breast Oncology, NHO Shikoku Science Center, Kochi, Japan. 6. Department of Breast Oncology, NHO Shikoku Science Center, Kochi, Japan. 701-0192, Japan. 701-019 Cancer Center, Matsuyama, Japan. 7. Department of Breast and Thyroid Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 7. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surgery, Red Cross Okayama, Japan. 8. Department of Breast and Endocrine Surger

## Background


Breast cancer-related lymphedema (BCRL) is a complication in patients who received breast cancer surgeries<sup>1)</sup>. A meta-analysis showed that the incidence of BCRL ranged between 8.4–21.4%<sup>2)</sup>. Regular physical activity (PA) have various beneficial effects on breast cancer patients<sup>3)</sup>. Several studies indicated that exercise might reduce the incidence of lymphedema<sup>4,5)</sup>. However, it is unclear the association between higher PA and preventive effect on BCRL. The aim of this study was to investigate the effectiveness of long-term PA after exercise and educational programs on BCRL.

## Methods

This study was secondary analyses from a prospective randomized controlled trial evaluating the efficacy of exercise and educational programs on long-term PA compared with usual care. Participants with stage 0–III breast cancer were randomly assigned in this study. The secondary endpoint was to assess the incidence of and preventive effect on BCRL at 1year after intervention.

BCRL was measured the ways with arm-circumference measurements. Arm-circumference measurements were taken on both arms at 4 points: the circumference of the thumb base or the metacarpophalangeal joints, the wrist joints, 5 cm distal to the midpoint of the lateral epicondyle, and 10 cm proximal to the midpoint of the lateral epicondyle. BCRL was defined as a difference of greater than 2.0 cm between the affected and non-affected arm circumferences at any of measurement points.

Participants in the control group were provided with an educational brochure on lifestyle after breast cancer treatment without any additional direct instruction by medical staff. In the education group, participants had to attend at least one instructional class on lifestyle (exercise and diet) for breast cancer survivors by breast medical doctors within 3 months of registration using an educational brochure. In the exercise program group, participants received a 30-min exercise program consisting of three parts, including aerobic exercise, workout, and stretching, three times a week for 4 months (16 weeks).



#### We enrolled breast cancer patients from March 2016 to March 2020 and randomly assigned them to the control (n = 111), education (n = 115), or exercise (n = 104) group.

## Figure.1 Participants' flowchart


Age (ye BMI (k Obesit

## Table1. Patient characteristics at hasoline

		Control	Education	Exercise	
С	haracteristic	group	group	group	P value
		<b>–</b> –	N = 115 (%)		i value
Age (ye	pars)	N = 111 (70)			
	mean (SD)	55 2 (11 3)	54.4 (10.8)	55 4 (10 4)	0.75*
BMI (kg	· · · ·	55.2 (11.5)	34.4 (10.0)	33.4 (10.4)	
	mean (SD)	23.3 (3.8)	23.0 (3.1)	23.3 (3.4)	0.77*
Obesity		23.3 (3.0)	23.0 (3.1)	23.3 (3.4)	
Obesity		72 (65 9)	96 (75 1)	74 (74 2)	0.28
	Non-obesity Obesity	73 (65.8) 28 (24-2)	· · ·		0.20
61000	Obesity	38 (34.2)	28 (24.6)	30 (28.8)	
Stage	0	11 (0 0)	11 (0 C)	44 (42 5)	
	0	11 (9.9)	11 (9.6) 50 (42 5)	14 (13.5) 47 (45.2)	
	I II	56 (50.5)	• •	• •	0.74
		33 (29.7)		• •	
		11 (9.9)	10 (8.7)	12 (11.5)	
	missing	-	1 (0.9)	-	
breast	surgery		60 /60 4)		0.00
	mastectomy	65 (58.6)	68 (59.1) 47 (40.0)	60 (57.7)	0.98
<b>.</b>	breast conserving surgery	46 (41.4)	47 (40.9)	44 (42.3)	
Surgica					0.40
	right	62 (55.9)	53 (46.1)	46 (44.2)	0.18
•	left	49 (44.1)	62 (53.9)	58 (55.8)	
Surgery	y for axilla				
	axillary dissection	33 (29.7)	38 (33.0)	34 (32.7)	
	sentinel node biopsy	76 (68.5)	76 (66.1)	66 (63.5)	0.59
	no axillary surgery	2 (1.8)	1 (0.9)	4 (3.8)	
Numbe	r of axillary lymph node metasta		()	( )	
	0	80 (72.1)	83 (72.2)	76 (73.1)	
	1–3	20 (18.0)	21 (18.3)	20 (19.2)	0.80
	4–10	4 (3.6)	7 (6.1)	4 (3.8)	
	Over 10	3 (2.7)	2 (1.7)	-	
	missing	4 (3.6)	2 (1.7)	4 (3.8)	
Estroge	en receptor status				
	positive	89 (80.2)	92 (80.0)	81 (77.9)	0.70
	negative	22 (19.8)	22 (19.1)	23 (22.1)	••
	unknown	-	1 (0.9)	-	
Proges	terone receptor status				
	positive	82 (73.9)	80 (69.6)	77 (74.0)	0.66
	negative	29 (26.1)	34 (29.6)	27 (26.0)	
	Unknown	-	1 (0.9)	-	
HER2 s	tatus				
	positive	32 (28.8)	18 (15.7)	23 (22.1)	0.027
	negative	75 (67.6)	93 (80.9)	71 (68.3)	0.027
	Unknown	4 (3.6)	4 (3.5)	10 (9.6)	
(Neo) a	djuvant chemotherapy				
	yes	58 (52.3)	60 (52.2)	52 (50.0)	0.93
	no	53 (47.7)	55 (47.8)	52 (50.0)	
Doceta	xel for (neo) adjuvant chemother	ару			
	yes	26 (23.4)	23 (20.0)	18 (17.3)	0.54
	no	85 (76.6)	92 (80.0)	86 (82.7)	
Endocr	ine therapy				
	yes	82 (73.9)	89 (77.4)	71 (68.3)	0.71
	no	29 (26.1)	26 (22.6)	33 (31.7)	
Radioth	nerapy				
	yes	59 (53.2)	72 (62.6)	55 (52.9)	0.25
	no	52 (46.8)	43 (37.4)	49 (47.1)́	

#### 52 (46.8) 43 (37.4) 49 (47.1) SD, standard deviation; BMI, body mass index; HER2, human epidermal growth factor receptor type2. \*: P values were calculated by Kruskal-Wallis test

#### Figure 2. Percentage of patients with breast cancerrelated lymphoedema at each measurement points



There were no significant differences in the incidence of BCRL at 1 year between the exercise and control groups (9.8% and 10.8%, P = 0.83) and between the education and control groups (11.6% and 10.8%, P =1.00)

## Table2. Univariate and multivariate analyses for the lymphedema at baseline


	Univariate Analysis			Multivariate Analysis		
	HR	95%CI	р	HR	95%CI	р
Age	1.01	0.99–1.03	0.25			
Breast surgery (Mastectomy vs. Breast conserving)	1.51	0.96–2.35	0.072	1.21	0.75–1.95	0.45
Obesity rate (Obesity vs. Non-Obesity)		1.13–2.69	0.013	1.65	1.07–2.56	0.024
Surgery for axilla (Axillary dissection vs. SNB or no surgery)		1.60–3.77	<0.001	2.11	1.34–3.31	0.001
(Neo) adjuvant chemotherapy (yes vs. no)	1.07	0.70–1.65	0.75			
Docetaxel for (neo) adjuvant chemotherapy (yes vs. no)	0.85	0.49–1.46	0.55			
Endocrine therapy (yes vs. no)	0.78	0.49–1.22	0.27			
Radiotherapy (yes vs. no)	1.44	0.92-2.24	0.11			
Physical activity (>5 vs. ≤5METs/week)	0.87	0.55–1.36	0.53			
Intervention						
Exercise vs. Control	1.26	0.73–2.15	0.41			
Education vs. Control	1.32	0.78–2.21	0.30	1.21	0.75–1.95	0.45
CI, confidence interval; HR, hazard ratio; METs, met	abolic equ	ivalents; SNB, s	sentinel node	e biopsy		
					Conc	lus

Although the effectiveness of long-term PA after intervention on BCRL was not observed, among patients with axillary dissection, the high PA at baseline compared to the low PA may have a lower BCRL. Future studies to investigate appropriate interventions and subgroups to prevent on BCRL should be needed.

1. Hayes SC, et al: Lymphedema after breast cancer: incidence, risk factors, and effect on upper body function. J Clin Oncol 26 (21):3536-3542, 2008 2. DiSipio T, et al: Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol 14 (6):500-515, 2013


- 3. Yildiz Kabak V, et al: Physical activity level, exercise behavior, barriers, and preferences of patients with breast cancer-related lymphedema. Support Care Cancer 29 (7):3593-3602, 2021

## Results



There were no significant differences in time to onset of BCRL from surgery between the exercise and control groups (event rate at 1 year: 21.3% and 16.4%, log-rank, P = 0.41) and between the education and control groups (event rate at 1 year: 20.9% and 16.4%, log-rank, P = 0.30). The incidence of BCRL in patients with axillary dissection and obesity was significantly higher compared with that in patients with sentinel node biopsy or no surgery (25.9% and 16.5%, log-rank P < 0.001) and non-obesity (27.3% and 15.9%, log-rank P = 0.012), respectively.

## Figure 4. Time to onset of lymphedema in patients who received axillary dissection by physical activity at baseline



#### References

4. Schmitz KH, et al: Weight lifting for women at risk for breast cancer-related lymphedema: a randomized trial. Jama 304 (24):2699-2705, 2010. 5. Torres Lacomba M, et al: Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial. Bmj 340:b5396, 2010.

Corresponding author

Shogo Nakamoto, M.D.

2-5-1, Shikata-cho, Kita-ku, Okayama 700-8558, Japa Phone: +81-86-235-6502 Fax: +81-86-235-6502 E-mail: p92c9f20@s.okayama-u.ac.jp

## Figure 3. Time to onset of lymphedema by interventions (A), surgery for axilla (B), obesity rate (C)

Additional analyses focused on patients who underwent axillary dissection showed that the high PA at baseline had a significantly lower BCRL event rate compared to the low PA (log-rank, P = 0.049)

METs, metabolic equivalents; PA, physical activity SNE

Acknowledgements

The results of this research were presented in Japanese a the 2021 Chugoku-Shikoku Breast Cancer Society Regiona Meeting. This study was conducted as a research support project for the Setouchi Breast Project Comprehensive Support Organization and was supported by JSPS KAKENHI Grant Number 15K01714 and 19K10622